Nebraska Cancer Specialists First in Region to Offer New Pancreatic Cancer Therapy

Nebraska Cancer Specialists (NCS) is now offering eligible patients access to a promising investigational treatment for metastatic pancreatic cancer through a U.S. Food and Drug Administration (FDA) Expanded Access Program (EAP). NCS is currently the only practice in the region providing access to this treatment through its nationally recognized clinical research program.